Compare · CERS vs VRSN
CERS vs VRSN
Side-by-side comparison of Cerus Corporation (CERS) and VeriSign Inc. (VRSN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and VRSN operate in EDP Services (Technology), so they compete in similar markets.
- VRSN is the larger of the two at $25.48B, about 43.4x CERS ($587.1M).
- Over the past year, CERS is up 116.2% and VRSN is down 8.5% - CERS leads by 124.6 points.
- VRSN has been more active in the news (17 items in the past 4 weeks vs 3 for CERS).
- VRSN has more recent analyst coverage (7 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- VeriSign Inc.
- Price
- $2.94+2.08%
- $280.16+7.21%
- Market cap
- $587.1M
- $25.48B
- 1M return
- +11.57%
- +11.18%
- 1Y return
- +116.18%
- -8.47%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 1998
- News (4w)
- 3
- 17
- Recent ratings
- 4
- 7
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
VeriSign Inc.
VeriSign, Inc., together with its subsidiaries, provides domain name registry services and internet infrastructure that enables internet navigation for various recognized domain names worldwide. It enables the security, stability, and resiliency of internet infrastructure and services, including providing root zone maintainer services, operating two of the 13 internet root servers; and offering registration services and authoritative resolution for the .com and .net domains, which support global e-commerce. VeriSign, Inc. was incorporated in 1995 and is headquartered in Reston, Virginia.
Latest CERS
- Chief Executive Officer Jayaraman Vivek K sold $52,665 worth of shares (16,666 units at $3.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.74% to 2,232,211 units (SEC Form 4)
- Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Green Kevin Dennis sold $99,105 worth of shares (33,676 units at $2.94) as part of a pre-agreed trading plan and gave a grant of 63,600 shares, decreasing direct ownership by 8% to 1,062,188 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Jayaraman Vivek K was granted 554,529 shares, gave a grant of 80,000 shares and sold $124,658 worth of shares (42,359 units at $2.94) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 2,248,877 units (SEC Form 4) to satisfy withholding obligation
- Chief Legal Officer Jensen Chrystal gave a grant of 55,000 shares and sold $71,598 worth of shares (24,329 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 966,657 units (SEC Form 4) (for withholding tax)
- President and CEO Greenman William Mariner gave a grant of 192,500 shares and sold $299,937 worth of shares (101,919 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 5,053,036 units (SEC Form 4) to cover taxes
- Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
- Director Bjerkholt Eric sold $53,180 worth of shares (20,454 units at $2.60), decreasing direct ownership by 7% to 261,679 units (SEC Form 4)
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest VRSN
- DNIB.com Reports Internet Has 401.6 Million Domain Name Registrations at the End of the Second Quarter of 2026
- SEC Form 10-Q filed by VeriSign Inc.
- VeriSign Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Verisign Reports Second Quarter 2026 Results
- Verisign Announces Delegation of .Web
- Director Mccann Debra was granted 900 shares, increasing direct ownership by 48% to 2,780 units (SEC Form 4)
- Director Desch Matthew J was granted 900 shares, increasing direct ownership by 124% to 1,628 units (SEC Form 4)
- Director Gorelick Jamie S was granted 900 shares (SEC Form 4)
- Director Cote Kathleen A was granted 900 shares, increasing direct ownership by 3% to 29,125 units (SEC Form 4)
- Director Buchalter Yehuda Ari was granted 900 shares, increasing direct ownership by 20% to 5,514 units (SEC Form 4)